Literature DB >> 19645022

18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.

Jean-Louis Alberini1, Florence Lerebours, Myriam Wartski, Emmanuelle Fourme, Elise Le Stanc, E Gontier, O Madar, P Cherel, A P Pecking.   

Abstract

BACKGROUND: : To prospectively assess fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) staging and prognosis value in patients with suspected inflammatory breast cancer (IBC).
METHODS: : Sixty-two women (mean age 50.7 +/- 11.4 years) presenting with unilateral inflammatory breast tumors (59 invasive carcinomas; 3 mastitis) underwent a PET/CT scan before biopsy.
RESULTS: : PET/CT scan was positive for the primary malignant tumor in 100% and false positive in 2 of 3 benign mastitis. In 59 IBC patients, FDG nodal foci were detected in axillary (90%; n = 53) and extra-axillary areas (56%; n = 33) ipsilateral to the cancer. Compared with clinical examination, the axillary lymph node status by PET/CT was upstaged and downstaged in 35 and 5 patients, respectively. In 7 of 9 N0 patients, the axillary lymph node positivity on PET/CT was correct, as revealed by pathological postsurgery assessment (not available in the 2 remaining patients). The nodal foci were compared with preoperative fine needle aspiration and/or pathological postchemotherapy findings available in 44 patients and corresponded to 38 true positive, 4 false-negative, and 2 false-positive cases. In 18 of 59 IBC patients (31%), distant lesions were found. On the basis of a univariate analysis of the first enrolled patients (n = 42), among 28 patients who showed intense tumoral uptake (standard uptake value(max)>5), the 11 patients with distant lesions had a worse prognosis than the 17 patients without distant lesions (P = .04).
CONCLUSIONS: : FDG-PET/CT imaging provides additional invaluable information regarding nodal status or distant metastases in IBC patients and should be considered in the initial staging. It seems also that some prognostic information can be derived from FDG uptake characteristics. Cancer 2009. (c) 2009 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19645022     DOI: 10.1002/cncr.24534

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  29 in total

1.  Initial staging impact of fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced breast cancer.

Authors:  Naoki Niikura; Jun Liu; Colleen M Costelloe; Shana L Palla; John E Madewell; Naoki Hayashi; Tse-Kuan Yu; Yutaka Tokuda; Richard L Theriault; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Oncologist       Date:  2011-05-31

2.  Semiquantitative analysis of maximum standardized uptake values of regional lymph nodes in inflammatory breast cancer: is there a reliable threshold for differentiating benign from malignant?

Authors:  Selin Carkaci; Beatriz E Adrada; Eric Rohren; Wei Wei; Mohammad A Quraishi; Osama Mawlawi; Thomas A Buchholz; Wei Yang
Journal:  Acad Radiol       Date:  2012-02-01       Impact factor: 3.173

Review 3.  Present and future role of FDG-PET/CT imaging in the management of breast cancer.

Authors:  Kazuhiro Kitajima; Yasuo Miyoshi
Journal:  Jpn J Radiol       Date:  2016-01-05       Impact factor: 2.374

4.  ¹⁸F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.

Authors:  Alexandre Cochet; Inna Dygai-Cochet; Jean-Marc Riedinger; Olivier Humbert; Alina Berriolo-Riedinger; Michel Toubeau; Séverine Guiu; Charles Coutant; Bruno Coudert; Pierre Fumoleau; François Brunotte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-07       Impact factor: 9.236

5.  (18) F-FDG PET/CT for initial staging in breast cancer patients - Is there a relevant impact on treatment planning compared to conventional staging modalities?

Authors:  J Krammer; A Schnitzer; C G Kaiser; K A Buesing; E Sperk; J Brade; S Wasgindt; M Suetterlin; S O Schoenberg; E J Sutton; K Wasser
Journal:  Eur Radiol       Date:  2015-02-15       Impact factor: 5.315

6.  FDG-PET/CT for systemic staging of patients with newly diagnosed breast cancer.

Authors:  David Groheux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08       Impact factor: 9.236

7.  Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.

Authors:  David Groheux; Sylvie Giacchetti; Jean-Luc Moretti; Raphael Porcher; Marc Espié; Jacqueline Lehmann-Che; Anne de Roquancourt; Anne-Sophie Hamy; Caroline Cuvier; Laetitia Vercellino; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-06       Impact factor: 9.236

8.  Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.

Authors:  C Riegger; J Herrmann; J Nagarajah; J Hecktor; S Kuemmel; F Otterbach; S Hahn; A Bockisch; T Lauenstein; G Antoch; T A Heusner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-06       Impact factor: 9.236

9.  FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer.

Authors:  Naoki Niikura; Colleen M Costelloe; John E Madewell; Naoki Hayashi; Tse-Kuan Yu; Jun Liu; Shana L Palla; Yutaka Tokuda; Richard L Theriault; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Oncologist       Date:  2011-07-17

10.  The Role of F-FDG-Positron Emission Tomography/Computed Tomography in Staging Primary Breast Cancer.

Authors:  Naoki Niikura; Naoto T Ueno
Journal:  J Cancer       Date:  2010-06-22       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.